A phase I clinical and pharmacokinetic study of brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule
- 1 October 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (10) , 1403-1411
- https://doi.org/10.1016/0277-5379(89)90097-7
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I studyEuropean Journal of Cancer and Clinical Oncology, 1989
- Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)Investigational New Drugs, 1987
- MECHANISM OF ACTION OF THE NOVEL ANTICANCER AGENT 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYL-4-QUINOLINECARBOXYLIC ACID SODIUM-SALT (NSC 368390) - INHIBITION OF DENOVO PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS1986
- EORTC guidelines for phase I trials with single agents in adultsEuropean Journal of Cancer and Clinical Oncology, 1985
- Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC breast cancer coooperative groupEuropean Journal of Cancer and Clinical Oncology, 1985
- ACTIVITY OF A NOVEL 4-QUINOLINECARBOXYLIC ACID, NSC-368390 [6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYL-4-QUINOLINECARBOXYLIC ACID SODIUM-SALT], AGAINST EXPERIMENTAL-TUMORS1985
- The Variability of Individual Tolerance to Methotrexate in Cancer PatientsBritish Journal of Cancer, 1971